The levels of calmodulin and calmodulin-binding proteins have been determined in cultured skin fibroblasts from patients with cystic fibrosis (CF) and age-and sex-matched controls. Calmodulin ranged from 0.20 to 0.76 Ag/mg protein; there was no difference between calmodulin concentration in fibroblasts from CF patients and controls. Calmodulin-binding proteins of 230, 212, 204, 164, 139, 70, 59, 46.5 
appear to be defective in their regulatory properties. These results suggest that the defect is not in the chloride channel itself but in its regulation by intracellular messengers.
Calmodulin, a Ca2 -binding protein found throughout the eukaryotes, serves as a primary intracellular receptor for Ca2+. The Ca2+/calmodulin complex interacts with various intracellular proteins, many ofwhich are enzymes and structural proteins of known physiological function (17) . Studies using calmodulin antagonists suggest that calmodulin may be a component ofthe Ca2+-dependent regulation ofchloride secretion in intestinal tissue (14, 18, 19) . Furthermore, rats chronically treated with reserpine to induce a cystic fibrosis-like hypersecrection of mucus seem to be deficient in a calmodulin-dependent regulatory mechanism that controls mucous glycoprotein secretion (20) . Using a calmodulin-dependent phosphodiesterase assay system to quantitate calmodulin, Gnegy et al. (21) reported that the calmodulin concentration in fibroblasts from cystic fibrosis patients was elevated over that of cells from controls. We have reinvestigated the level of calmodulin in cystic fibrosis and normal fibroblasts with a specific radioimmunoassay; in addition, we have identified calmodulin-binding proteins in both cystic fibrosis and control fibroblasts and compared their levels. We find no significant difference in the average levels ofcalmodulin in cystic fibrosis vs. control fibroblasts. However, we did find that the binding of '251-calmodulin to a protein of 46.5 kD is significantly depressed in fibroblasts from cystic fibrosis patients. This observation may be important regarding identification of the primary genetic defect responsible for cystic fibrosis.
Methods
Chemicals. ['251 ]NaI (13-17 mCi/jig) was purchased from Amersham Corp., Arlington Heights, IL. Tris buffer, calcium chloride, nonidet P-40, EGTA, EDTA, Triton X-100, and Protein A were purchased from Sigma Chemical Co., St. Louis, MO. Phenyl-Sepharose was purchased from Pharmacia, Inc., Piscataway, NJ. Electrophoresis reagents were purchased from Bio-Rad Laboratories, Richmond, CA. Nitrocellulose sheets (0.45 ,uM pore) were purchased from Sartorius Inc., Hayward, CA. Trifluoperazine was provided free of charge by SmithKline Laboratories, Philadelphia, PA.
atrics. Cultures were maintained in Dulbecco's modified Eagle's medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO2 at 370C.
Each experiment was conducted with a matched pair of cell lines of the same passage number. Upon reaching confluence, cells were scraped into an ice-cold phosphate-buffered saline (PBS) solution (20 mM sodium phosphate, pH 7.2, 0.15 M NaCI), collected by centrifugation at 2,000 g for 5 min and resuspended in 50 mM Tris-HCl, pH 7.8, 3 mM EGTA. For radioimmunoassays and gel electrophoresis, the resuspended cells were solubilized by the addition of sodium dodecyl sulfate (SDS) to 0.25% and were incubated for 2 min in boiling water. For the determination of phosphatase enzyme activity, the cells were homogenized in a glass/teflon tissue homogenizer, lysed by two cycles of freezing in dry ice/methanol and rapid thawing, and assayed immediately for activity.
Radioimmunoassays. We used a detergent-modified radioimmunoassay for the calmodulin-dependent protein phosphatase to measure phosphatase levels (24); bovine brain phosphatase was used as a standard (23) . The calmodulin radioimmunoassay as described by Wallace and Cheung (25) was modified in a manner analogous to the phosphatase radioimmunoassay to allow the inclusion of0.2% SDS from the detergentsolubilized fibroblast samples (unpublished data) and used to measure the calmodulin concentration; bovine brain calmodulin was used as a standard.
Identification ofcalmodulin-binding proteins. 
Results
The concentration of calmodulin was determined in fibroblasts from patients with cystic fibrosis and from age-and sex-matched controls using a specific radioimmunoassay. The (Fig. 1) .
The identification of a 59-kD calmodulin-binding protein in fibroblasts suggested that these cells might contain a calmodulin-dependent protein phosphatase similar to the well-characterized phosphatase from bovine brain that contains a 60-kD calmodulin-binding subunit (32, 33) . A polyclonal antibody specific for the 60-kD subunit of bovine brain calmodulin-dependent phosphatase bound to a fibroblast protein with a mobility identical to the 59-kD calmodulin-binding protein (Fig.  1, panel C) bound to the 59-kD protein equivalently in control and cystic fibrosis fibroblasts. Assuming that the 59-kD calmodulin-binding protein is subunit A of a calmodulin-dependent phosphatase, these data are consistent with the radioimmunoassay and enzyme assay data described above.
Discussion
Although the calmodulin concentration in human fibroblasts ranged from 0.20 to 0.76 ug/mg protein, we found no significant difference between its average concentration in fibroblasts from cystic fibrosis patients and controls. These results contrast markedly to those ofGnegy et al. (21), who found a 60% increase in the level of calmodulin in cystic fibrosis fibroblasts over that ofcontrol fibroblasts. Our cell lines have been carefully matched with regard to the age and sex of the donor, the number of passages in culture, and the growth stage at which the cells were harvested. Variations in any of these factors could account for the differences observed by Gnegy et al. (21) . In addition, we found significantly lower levels of calmodulin than reported by Gnegy et al. (21), a difference which is most likely due to differences in the techniques used to measure calmodulin. While Gnegy et al. (21) used a calmodulin-dependent phosphodiesterase system that measures calmodulin based upon the degree of enzyme stimulation by a heat-treated extract, we used a specific radioimmunoassay. The enzyme-based assay is subject to interferences by both lipids and proteolytic enzymes, which stimulate phosphodiesterase and result in anomalous overestimations of the calmodulin concentration (34); these interferences are not a problem in the radioimmunoassay. An alteration in calmodulin does not appear to be the genetic defect responsible for cystic fibrosis. Instead, evidence obtained by a genetic linkage approach indicates that the locus for the defective gene in cystic fibrosis is on a specific region of chromosome seven (35- modulin bound could represent a reduction in the affinity for and/or capacity of the 46.5-kD protein to bind calmodulin. Either of these factors could be affected by a mutation in the gene that codes for the 46.5-kD calmodulin-binding protein or by an alteration in its degree of phosphorylation. Phosphorylation has been shown to decrease the affinity ofseveral calmodulin-binding proteins for calmodulin (38, 39) .
Although the biochemical defect in cystic fibrosis is unknown, patients exhibit alterations in the electrolyte compositions of their secretory fluids that may result from a reduction in the epithelial permeability ofchloride (1-7). Frizzell et al. (16) demonstrated that epithelial cells from patients with cystic fibrosis contain chloride channels that are biophysically similar to channels from unaffected individuals and are regulated by Ca2', possibly through a calmodulin-dependent mechanism, but have lost their ability to be regulated by cAMP. An alteration in the response of cystic fibrosis tissues to agonists whose affects are mediated by cAMP has also been demonstrated in the secretory coils ofsweat glands (40) , nasal epithelia (41), and cultured airway cells (42) . However, normal increases in the levels of cAMP were observed in all these systems. Thus, the cystic fibrosis genetic defect may lie in the pathway connecting cAMP to the regulation of the chloride channel. Cyclic AMP functions as an intracellular regulator by activating a cAMP-dependent protein kinase that in turn phosphorylates various proteins and alters their activities. Several calmodulin-dependent enzymes-myosin light chain kinase (38) and a Ca2"-dependent cyclic nucleotide phosphodiesterase (39)-are phosphorylated by the cAMP-dependent kinase with subsequent decreases in their affinities for calmodulin. Thus, the decreased binding of '251-calmodulin to a 46.5-kDa protein in cystic fibrosis fibroblasts could result from an alteration in the level of its phosphorylation by the cAMP-dependent kinase. Phosphorylation of the 46.5-kD calmodulinbinding protein (and ofseveral ofthe other fibroblast calmodulinbinding proteins) could also account for the appearance of doublets;' the phosphorylated and dephosphorylated forms of the proteins may exhibit slight differences in mobility on SDS gels. Moreover, since the genetic defect could be in the primary structure of the phosphorylation site, the altered level of '25I-calmodulin binding to the 46.5-kD protein could be a direct indication of the genetic defect responsible for cystic fibrosis. Alternatively, the altered binding may be due to a generalized secondary effect of the defective cystic fibrosis gene or a specific secondary effect present only in skin fibroblasts. The identity of the 46.5-kD calmodulin-binding protein, its presence or absence in epithelial secretory tissues, and its possible involvement in cystic fibrosis are currently under investigation in our laboratory.
